Add to ORKGEph, erythropoietin-producing hepatocellular; BRAFi’s, BRAF inhibitors; VEM, vemurafenib
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cancer cause of death in the US. Gemci...
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have...
abstRact BRAFV600E is the most common oncogenic lesion in melanoma and results in con-stitutive acti...
ABSTRACT BRAF V600E is the most common oncogenic lesion in melanoma and results in con-stitutive act...
The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resista...
Acquired BRAF/MAPK/extracellular signal‒regulated kinase inhibitor resistance in melanoma results in...
Acquired BRAF/MAPK/extracellular signal‒regulated kinase inhibitor resistance in melanoma results in...
Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but t...
Activating BRAF mutations occurs in 50–60% of malignant melanomas. Although initially treatable, the...
The RAS-RAF-MEK-ERK pathway is a key driver of proliferation and survival signals in tumor cells and...
Despite recent advancements in the treatment of late-stage mutant BRAF V600E/K melanomas, a major hu...
OBJECTIVE: The Eph-Ephrin system is involved on different biological cellular processes, but at the ...
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently...
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently...
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cancer cause of death in the US. Gemci...
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have...
abstRact BRAFV600E is the most common oncogenic lesion in melanoma and results in con-stitutive acti...
ABSTRACT BRAF V600E is the most common oncogenic lesion in melanoma and results in con-stitutive act...
The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resista...
Acquired BRAF/MAPK/extracellular signal‒regulated kinase inhibitor resistance in melanoma results in...
Acquired BRAF/MAPK/extracellular signal‒regulated kinase inhibitor resistance in melanoma results in...
Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but t...
Activating BRAF mutations occurs in 50–60% of malignant melanomas. Although initially treatable, the...
The RAS-RAF-MEK-ERK pathway is a key driver of proliferation and survival signals in tumor cells and...
Despite recent advancements in the treatment of late-stage mutant BRAF V600E/K melanomas, a major hu...
OBJECTIVE: The Eph-Ephrin system is involved on different biological cellular processes, but at the ...
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently...
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently...
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cancer cause of death in the US. Gemci...
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have...